MBOT Stock Price, Microbot Medical Inc Quote, Chart

Market Summary

USD0.88+0.02

Market Closed

2.33%

MBOT Stock Price

View Fullscreen

MBOT RSI Chart

MBOT Valuation

Market Cap

12.7M

Price/Earnings (Trailing)

-1.18

Price/Sales (Trailing)

117.86

Price/Free Cashflow

-1.48

MBOT Price/Sales (Trailing)

MBOT Profitability

Return on Equity

-238.61%

Return on Assets

-128.98%

Free Cashflow Yield

-67.6%

MBOT Fundamentals

MBOT Revenue

Revenue (TTM)

114.2K

MBOT Earnings

Earnings (TTM)

-10.7M

Earnings Growth (Yr)

-5.2%

Earnings Growth (Qtr)

-28.95%

Breaking Down MBOT Revenue

Last 7 days

1.2%

Last 30 days

-23.5%

Last 90 days

-30.7%

Trailing 12 Months

-44.3%

How does MBOT drawdown profile look like?

MBOT Financial Health

Current Ratio

2.09

Debt/Equity

0.05

Debt/Cashflow

-34.83

MBOT Investor Care

Shares Dilution (1Y)

77.10%

Diluted EPS (TTM)

-1.1

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2016	119.3K	118.5K	114.2K	0
2015	1.4M	994.0K	555.5K	116.9K
2014	943.5K	684.8K	442.0K	1.0M
2013	1.0M	1.0M	1.1M	1.2M
2012	1.6M	1.7M	1.7M	1.4M
2011	1.4M	1.4M	1.4M	1.2M
2010	0	1.1M	1.3M	1.4M
2009	0	0	0	992.9K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Microbot Medical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Oct 19, 2020	bornstein yoseph	sold	-38,734	7.9358	-4,881	-
Oct 12, 2020	bornstein yoseph	sold	-156,898	7.8449	-20,000	-
Oct 05, 2020	bornstein yoseph	sold	-156,898	7.8449	-20,000	-
Oct 05, 2020	bornstein yoseph	sold	-154,850	7.7425	-20,000	-
Aug 17, 2020	bornstein yoseph	sold	-154,093	10.192	-15,119	-
Dec 23, 2019	gadot harel	sold	-400,000	10.00	-40,000	chairman, president and ceo
Jan 16, 2019	alliance investment management ltd	bought	15,432	10.9916	1,404	-
Jan 16, 2019	alliance investment management ltd	sold	-76,288	10.3093	-7,400	-
Jan 15, 2019	alliance investment management ltd	bought	184,139	9.3982	19,593	-
Jan 15, 2019	alliance investment management ltd	sold	-1,220,170	11.778	-103,597	-

Which funds bought or sold MBOT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 24, 2024	AlphaCentric Advisors LLC	unchanged	-	-41,000	123,000	0.07%
Apr 24, 2024	Newbridge Financial Services Group, Inc.	unchanged	-	-1.00	1.00	-%
Apr 24, 2024	DIAMANT ASSET MANAGEMENT, INC.	new	-	12,300	12,300	0.01%
Apr 23, 2024	BFSG, LLC	new	-	1,230	1,230	-%
Apr 19, 2024	Taylor Frigon Capital Management LLC	sold off	-100	-20,500	-	-%
Apr 19, 2024	BOURGEON CAPITAL MANAGEMENT LLC	sold off	-100	-5.00	-	-%
Apr 15, 2024	KINGSWOOD WEALTH ADVISORS, LLC	new	-	12,300	12,300	-%
Mar 11, 2024	VANGUARD GROUP INC	added	75.85	390,403	753,660	-%
Feb 26, 2024	Virtu Financial LLC	added	75.87	36,000	69,000	-%
Feb 20, 2024	Pacific Center for Financial Services	unchanged	-	-	2.00	-%

Are Funds Buying or Selling MBOT?

Are funds buying MBOT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MBOT

No. of Funds

Unveiling Microbot Medical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	armistice capital, llc	4.99%	687,654	SC 13G/A
Feb 14, 2023	armistice capital, llc	9.99%	799,180	SC 13G
Jan 20, 2021	chasing value asset management inc.	8.6%	610,657	SC 13G
Jan 02, 2020	gadot harel	4.04%	296,463	SC 13D/A
Oct 21, 2019	mona joseph	5.69%	2,395,495	SC 13G

Recent SEC filings of Microbot Medical Inc

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	424B3	Prospectus Filed
Apr 24, 2024	8-K	Current Report
Apr 16, 2024	424B3	Prospectus Filed
Apr 15, 2024	8-K	Current Report
Apr 04, 2024	424B3	Prospectus Filed
Apr 03, 2024	EFFECT	EFFECT
Apr 01, 2024	S-1/A	Initial Public Offering
Mar 27, 2024	10-K	Annual Report
Feb 27, 2024	8-K	Current Report
Feb 26, 2024	4	Insider Trading

Peers (Alternatives to Microbot Medical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.5B	40.1B	-5.27%	-1.83%	32.59	4.65	-8.12%	-17.45%
BDX	66.9B	19.5B	-6.10%	-12.08%	53.25	3.43	4.02%	-22.04%
ALGN	23.2B	3.9B	-5.77%	-2.75%	52.14	6.01	3.42%	23.09%
BAX	20.4B	14.8B	-6.00%	-14.25%	7.67	1.38	2.12%	209.17%
MID-CAP
ATR	9.5B	3.5B	-0.91%	22.96%	30.27	2.67	6.16%	35.06%
HSIC	9.4B	12.3B	-2.70%	-9.94%	22.59	0.76	-2.44%	-22.68%
BIO	8.1B	2.7B	-21.14%	-36.84%	-12.64	3.01	-4.68%	82.43%
XRAY	6.3B	4.0B	-8.20%	-26.06%	-47.15	1.6	1.10%	85.84%
AXNX	3.4B	366.4M	-3.27%	17.57%	-560.12	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-7.27%	-4.94%	11.93	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-12.41%	-15.32%	-1.95	0.41	7.73%	-1066.14%
ANIK	379.4M	166.7M	0.04%	-0.97%	-4.59	2.28	6.67%	-456.34%
ANGO	232.3M	324.0M	1.75%	-30.04%	-1.21	0.72	-3.19%	-337.41%
APYX	49.9M	52.3M	2.13%	-52.32%	-2.67	0.95	17.61%	19.28%
AEMD	3.6M	3.7M	-20.47%	240.00%	-0.29	0.95	5.77%	8.23%

Microbot Medical Inc News

Latest updates

Microbot Medical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2016Q3	2016Q2	2016Q1	2015Q4	2015Q3	2015Q2	2015Q1	2014Q4	2014Q4	2014Q3	2014Q2	2014Q1	2013Q4	2013Q3	2013Q2	2013Q1	2012Q4	2012Q3	2012Q2	2012Q1	2011Q4
Revenue	11.8%	32,762	29,311	23,164	29,000	37,030	30,131	456,566	883,000	883,157	82,000	23,000	24,000	313,000	324,792	281,697	284,200	211,000	264,000	249,000	644,000	541,520
Gross Profit	-	-	-	-	-	-	-	-	-	-	211,501	164,107	252,204	226,110	239,049	204,124	217,359	156,029	192,104	184,557	572,077	494,099
Operating Expenses	-78.5%	1,912,631	8,913,264	9,837,039	8,528,000	10,024,961	9,302,714	8,981,387	10,612,000	10,611,875	6,462,000	7,983,000	6,866,000	9,341,000	6,628,000	6,131,000	6,165,000	6,949,000	5,269,000	5,534,000	5,898,000	7,807,408
Interest Expenses	21090.6%	27,124	128	27,901	-431,861	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-6.3%	8.00	9.00	11.00	6.00	10.00	7.00	11.00	14.00	17.00	20.00	22.00	24.00	26.00	28.00	30.00	31.00	37.00	11.00	13.00	14.00	6.00
Current Assets	-5.8%	8.00	8.00	10.00	6.00	9.00	7.00	10.00	13.00	16.00	19.00	21.00	23.00	25.00	27.00	29.00	30.00	36.00	10.00	12.00	13.00	6.00
Cash Equivalents	84.9%	2.00	1.00	6.00	2.00	2.00	4.00	7.00	10.00	13.00	13.00	16.00	18.00	20.00	27.00	28.00	30.00	29.00	4.00	5.00	5.00	5.00
Net PPE	-20.7%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	150.1%	4.00	2.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	6.00	5.00	5.00	5.00	5.00
Current Liabilities	153.9%	4.00	1.00	1.00	1.00	2.00	2.00	2.00	2.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	5.00	5.00	4.00	4.00	5.00
Shareholder's Equity	-38.8%	5.00	7.00	9.00	5.00	7.00	6.00	9.00	12.00	14.00	18.00	20.00	22.00	24.00	26.00	28.00	30.00	32.00	6.00	8.00	9.00	1.00
Retained Earnings	-4.1%	-79.50	-76.35	-73.90	-71.61	-68.76	-65.76	-62.29	-58.78	-55.59	-51.73	-49.18	-46.67	-44.28	-41.64	-39.17	-37.32	-35.11	-33.24	-31.37	-29.82	-27.86
Additional Paid-In Capital	0.4%	84.00	84.00	83.00	76.00	76.00	71.00	71.00	70.00	70.00	70.00	69.00	69.00	69.00	68.00	67.00	67.00	70.00	43.00	43.00	42.00	33.00
Shares Outstanding	0%	12.00	12.00	12.00	8.00	8.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	7.00	-	-	-	-	-	-	-	-
Float	-	-	-	38.00	-	-	-	35.00	-	-	-	56.00	-	-	-	46.00	-	-	-	20.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	-10.0%	-1,821	-1,655	-1,854	-3,203	-2,463	-2,955	-3,124	-3,007	-2,887	-2,176	-2,297	-1,994	-1,870	-1,694	-1,342	-2,346	-1,920	-1,331	-477	-2,723	-1,435
Share Based Compensation	-11.6%	297	336	349	412	430	461	432	429	370	307	299	410	469	559	566	343	193	296	295	315	260
Cashflow From Investing	215.0%	2,957	-2,572	-1,295	2,883	-3,753	-5.00	-62.00	-16.00	2,955	-14.00	-6.00	265	-5,006	-7.00	-8.00	2,253	43.00	-	-	-2,496	16.00
Cashflow From Financing	100.0%	-	-161	-	-	-	-	-	-	-	-	-	-	-	-	-	-3,375	27,208	-	-	9,562	-

MBOT Income Statement

2023-12-31

Consolidated Statements of Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Research and development, net	$ (5,724)	$ (7,736)
General and administrative, net	(4,131)	(5,545)
Operating loss	(9,855)	(13,281)
Financing income, net	228	118
Loss on disposal of property and equipment	(2)	(5)
Loss on legal settlement, net	(1,111)
Net loss	$ (10,740)	$ (13,168)
Basic net loss per share	$ (1.05)	$ (1.81)
Diluted net loss per share	$ (1.05)	$ (1.81)
Basic weighted average common shares outstanding	10,199,984	7,260,344
Diluted weighted average common shares outstanding	10,199,984	7,260,344

MBOT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 2,468	$ 2,442
Marketable securities	3,917	5,760
Short-term deposit		3
Restricted cash	49	77
Insurance recovery receivable related to legal settlement and legal expenses	1,335
Prepaid expenses and other current assets	152	532
Total current assets	7,921	8,814
Property and equipment, net	146	221
Operating right-of-use assets	260	502
Total assets	8,327	9,537
Current liabilities:
Trade accounts payables	357	116
Lease liabilities	191	283
Legal settlement accrual	2,211
Accrued liabilities	1,027	1,670
Total current liabilities	3,786	2,069
Non-current liabilities:
Long-term lease liabilities	40	179
Total liabilities	3,826	2,248
Commitments and contingencies
Shareholders’ equity:
Common stock; $0.01 par value; 60,000,000 shares authorized as of December 31, 2023 and 2022; 11,707,317 and 7,890,628 shares issued and outstanding as of December 31, 2023 and 2022, respectively.	118	80
Additional paid-in capital	83,884	75,970
Accumulated deficit	(79,501)	(68,761)
Total shareholders’ equity	4,501	7,289
Total liabilities and shareholders’ equity	$ 8,327	$ 9,537

About Microbot Medical Inc

Microbot Medical Inc. operates as a pre-clinical medical device company in the United Kingdom. It primarily engages in the research, design, and development of next generation robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company also offers LIBERTY, a robotic system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination. In addition, it provides One & Done Technology, an endovascular robotic system for a range of applications in cardiovascular, peripheral vascular, and neurovascular spaces; and NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. Further, the company offers ViRob, an autonomous crawling micro-robot which can be controlled remotely to navigate and crawl in different natural spaces within the human body, including blood vessels, digestive tract, and respiratory system, as well as artificial spaces, such as shunts, catheters, ports, etc. Additionally, it provides ipCAT, a disposable self-propelled locomotive device that is designed to advance in tubular anatomies. The company also has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is headquartered in Hingham, Massachusetts.

CEO	Mr. Harel Gadot
WEBSITE	https://microbotmedical.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	18

Microbot Medical Inc Frequently Asked Questions

What is the ticker symbol for Microbot Medical Inc? What does MBOT stand for in stocks?

MBOT is the stock ticker symbol of Microbot Medical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Microbot Medical Inc (MBOT)?

As of Fri Apr 26 2024, market cap of Microbot Medical Inc is 12.67 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MBOT stock?

You can check MBOT's fair value in chart for subscribers.

What is the fair value of MBOT stock?

You can check MBOT's fair value in chart for subscribers. The fair value of Microbot Medical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Microbot Medical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MBOT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Microbot Medical Inc a good stock to buy?

The fair value guage provides a quick view whether MBOT is over valued or under valued. Whether Microbot Medical Inc is cheap or expensive depends on the assumptions which impact Microbot Medical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MBOT.

What is Microbot Medical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Apr 26 2024, MBOT's PE ratio (Price to Earnings) is -1.18 and Price to Sales (PS) ratio is 117.86. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MBOT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Microbot Medical Inc's stock?

In the past 10 years, Microbot Medical Inc has provided -0.539 (multiply by 100 for percentage) rate of return.